

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Peijia Medical Limited

沛嘉醫療有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 9996)

VOLUNTARY ANNOUNCEMENT ACHIEVA MEDICAL ENTERED INTO AN EXCLUSIVE DISTRIBUTION AGREEMENT WITH B. BRAUN MEDICAL

This announcement is made by Peijia Medical Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to provide the shareholders of the Company and potential investors with updated information in relation to the latest business of the Group.

The board (the “**Board**”) of directors (the “**Directors**”) of the Company is pleased to announce that Shanghai Achieva Medical Suzhou Co., Ltd. (“**Achieva Medical**”), a subsidiary of the Company, entered into an exclusive distribution agreement (the “**Agreement**”) with B. Braun Medical (Shanghai) International Trading Co., Ltd. (“**B. Braun Medical**”).

Pursuant to the Agreement, Achieva Medical has obtained the exclusive distribution rights in the Chinese mainland for SeQuent® Please CIS Paclitaxel Drug-Coated Intracranial Balloon Dilatation Catheter (“**SeQuent® Please CIS**” or the “**Product**”), a product of B. Braun Medical.

SeQuent® Please CIS is an intracranial paclitaxel drug-coated balloon dilatation catheter developed based on B. Braun Medical’s mature drug-coated balloon (“**DCB**”) technology. During mechanical dilatation at the target lesion, the product will release the coated paclitaxel precisely to the diseased vascular wall, which will serve as antiproliferative agents to reduce neointimal hyperplasia effectively and lower the risk of restenosis in long term. The Product is specifically designed for the anatomical characteristics of intracranial vessels, including narrow and tortuous pathways, and is intended to provide an innovative “implant-free” treatment option for intracranial vascular diseases. As at the date of this announcement, the registration application for the Product has been submitted to the National Medical Products Administration of the People’s Republic of China.

B. Braun Medical is a global medical technology company with extensive experience in the field of DCB. Since launching one of the world's first commercialized DCBs in 2008, which is now the best investigated DCB in cardiology, B. Braun Medical has accumulated extensive clinical application experience and supporting clinical evidence globally across related products.

The cooperation with B. Braun Medical further enriches the Group's neurointerventional product portfolio and strengthens its strategic positioning in innovative intracranial intervention solutions. Leveraging Achieva Medical's local commercialization resources and academic promotion capabilities, the Group expects to accelerate the future clinical adoption of SeQuent® Please CIS upon regulatory approval and further strengthen the Group's positioning in the neurovascular intervention market.

To the best of the Directors' knowledge, information and belief, having made all reasonable enquiries, B. Braun Medical and its ultimate beneficial owners are third parties independent of the Company and its connected persons (as defined under the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "Listing Rules")).

The entering into of the Agreement does not constitute any notifiable transaction of the Company under Chapter 14 of the Listing Rules, nor any connected transaction under Chapter 14A of the Listing Rules.

SHAREHOLDERS OF THE COMPANY AND POTENTIAL INVESTORS ARE ADVISED TO EXERCISE DUE CARE WHEN DEALING IN THE SHARES OF THE COMPANY.

By order of the Board
Peijia Medical Limited
Dr. Yi ZHANG
Chairman and Executive Director

Hong Kong, June 1, 2026

As at the date of this announcement, the Board comprises Dr. Yi ZHANG, Mrs. Ping Ye ZHANG and Ms. Hong YE as executive Directors, Mr. Jifeng GUAN, Mr. Fei CHEN and Mr. Jun YANG as non-executive Directors, and Dr. Stephen Newman OESTERLE, Mr. Robert Ralph PARKS, Mr. Wai Ming YIP and Mr. Huacheng WEI as independent non-executive Directors.